GSK2881078
Aliases: GSK-2881078
Last verified: 2026-09-23
The short version
A GSK SARM in development for cachexia (COPD/cancer) — Phase I/II show lean-mass gains with tolerability. Status: in clinical trials. Not approved; WADA-banned (S1).
Identity & type
- Molecular type
- SARM
- Origin
- A GSK SARM in development for cachexia (COPD/cancer) — Phase I/II show lean-mass gains with tolerability.
Mechanism of action
Selective AR agonism.
Dosing & routes
Official / clinical context
No approved official document exists for GSK2881078. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Trials: 0.5–4 mg/day. Not present in communities (pharma program); experiences are rare and unverified.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Not present in communities (pharma program); experiences are rare and unverified.
Protocol — official vs community
Official / label
No official protocol exists — this compound has no approved product.
Community (anecdotal)
Structured protocol data for this entry is coming.
Human evidence
Phase I/II programs.
Preclinical evidence
Preclinical literature preceded the clinical trials; details vary by compound.
Known risks
- Moderate suppression, lipid changes at higher doses.characterized
- WADA prohibition (S1 anabolic agents)characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term safety in off-label use
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.